Why Is ARTL Stock Soaring Pre-Market Today?

Artelo Biosciences secured a fully-funded study to evaluate the effects of its peripherally selective synthetic cannabinoid, ART27.13, in patients with glaucoma or ocular hypertension.
Trending stock
Stock chart (Image Courtesy: Getty Images)
Profile Image
Rounak Jain·Stocktwits
Published Mar 18, 2026   |   8:00 AM EDT
Share
·
Add us onAdd us on Google

Artelo Biosciences Inc. (ARTL) on Wednesday announced that it has secured a fully funded glaucoma study following an agreement with Glaucoma UK and the HSC R&D Division.

The study will evaluate the effects of Artelo’s peripherally selective synthetic cannabinoid, ART27.13, in patients with glaucoma or ocular hypertension.

Artelo Biosciences shares were up more than 40% in Wednesday’s pre-market trade. Retail sentiment on Stocktwits around the company trended in the ‘extremely bullish’ territory with message volumes at ‘high’ levels at the time of writing.

Get updates to this story developing directly on Stocktwits.

Also See: Palladyne AI Subsidiary Wins US Navy Contract For Developing New Missiles — PDYN Stock Soars Pre-Market

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Share
·
Add us onAdd us on Google
Read about our editorial guidelines and ethics policy